TEVA
HealthcareTeva Pharmaceutical Industries Limited · Drug Manufacturers - Specialty & Generic · $40B
What is Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries is a global pharmaceutical company headquartered in Tel Aviv, Israel, operating across North America, Europe, and international markets with a broad portfolio of generic and specialty medicines.
Teva generates revenue by developing, manufacturing, and distributing generic medicines, specialty branded drugs, and active pharmaceutical ingredients. Its specialty focus spans central nervous system disorders, respiratory conditions, and oncology. Key branded products address multiple sclerosis, migraine prevention, tardive dyskinesia, and asthma, while its generics business serves patients and healthcare systems seeking lower-cost treatment options.
Founded in 1982, Teva has grown into one of the world's largest generic drug manufacturers.
- Generic and branded pharmaceuticals across multiple dosage forms
- CNS therapies including AJOVY and AUSTEDO
- Respiratory treatments including ProAir and QVAR product lines
- Active pharmaceutical ingredients (API) manufacturing
Is TEVA a Good Stock to Buy?
UQS Score rates TEVA as Below Average overall.
Valuation stands out as the most favorable pillar, suggesting the market may already be pricing in many of Teva's challenges. Quality and Growth both register as Neutral, indicating neither a clear drag nor a standout advantage in those areas.
Moat and Risk are both rated Weak, reflecting the competitive pressures generic drug manufacturers face and the financial and legal headwinds that have weighed on Teva in recent years.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does TEVA pay dividends?
No — Teva Pharmaceutical Industries Limited does not currently pay a dividend.
Teva does not currently pay a dividend. The company has prioritized debt reduction and operational restructuring over returning cash to shareholders. Income-focused investors should factor this into their assessment when comparing TEVA to other large-cap healthcare names.
When does TEVA report earnings?
Teva Pharmaceutical reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Results in recent periods have reflected the ongoing tension between generic pricing pressure and growth from specialty brands. Progress on debt reduction and cost restructuring has been a recurring theme in management commentary.
For the most recent quarter's results and guidance, visit Teva Pharmaceutical's investor relations page directly.
TEVA Price History
+201.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Teva Pharmaceutical Industries Limited?
Based on Teva Pharmaceutical Industries Limited's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Teva Pharmaceutical do?
Teva develops, manufactures, and sells generic medicines, specialty branded drugs, and active pharmaceutical ingredients globally. Its specialty portfolio focuses on central nervous system conditions, respiratory diseases, and oncology, while its generics business serves cost-sensitive healthcare markets worldwide.
Does TEVA pay dividends?
No, Teva does not currently pay a dividend. The company has been focused on reducing its debt load and restructuring operations, leaving dividend reinstatement as a longer-term consideration rather than a near-term priority.
When does TEVA report earnings?
Teva reports on a quarterly basis. Specific upcoming dates are best confirmed on Teva's official investor relations page, as our data source does not cover forward-looking earnings calendar dates.
Is TEVA a good stock to buy?
UQS Score rates TEVA as Below Average based on its 5-pillar composite. Valuation is rated Good, but Moat and Risk are both Weak. Whether that trade-off suits your portfolio depends on your risk tolerance. The full pillar breakdown is available to Pro members.
Is TEVA overvalued?
The UQS Valuation pillar for TEVA is rated Good, suggesting the current price reflects a relatively attractive entry point relative to fundamentals. However, valuation alone does not offset weaker scores in Moat and Risk.
What is TEVA's market cap bracket?
Teva Pharmaceutical is classified as a large-cap company, placing it among the larger publicly traded pharmaceutical firms globally despite the financial challenges it has navigated in recent years.
Is TEVA a long-term quality investment?
As a long-term quality indicator, UQS Score rates TEVA Below Average. Weak Moat and Risk scores suggest structural challenges that long-term investors should weigh carefully. The Good Valuation rating may offer some cushion, but quality consistency remains a concern.
What sector does TEVA belong to?
Teva operates in the Healthcare sector, specifically within the pharmaceutical industry. It competes across both the generic drug market and the branded specialty pharmaceutical space, giving it a broader footprint than pure-play specialty pharma peers.
Unlock Full TEVA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete 5-pillar UQS Score breakdown for TEVA
- ✓Access detailed financial metrics behind each pillar rating
- ✓Compare TEVA side-by-side with peers in the Healthcare sector
- ✓Screen for higher-quality alternatives using UQS preset filters
Pro Analysis
TEVA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 41.7 | 58.7 | 25.0 | 44.5 | 8.5 | 70.3 | +3.3 |
| May 10, 2026 | 38.4 | 13.9 | 25.0 | 44.5 | 39.1 | 92.8 | 0.0 |
| May 8, 2026 | 38.4 | 13.9 | 25.0 | 44.5 | 39.1 | 92.4 | -2.9 |
| May 7, 2026 | 41.3 | 55.9 | 25.0 | 44.5 | 8.4 | 72.5 | -0.3 |
| May 4, 2026 | 41.6 | 55.9 | 25.0 | 44.5 | 8.4 | 74.9 | -0.4 |
| May 3, 2026 | 42.0 | 55.9 | 25.0 | 46.3 | 8.4 | 75.1 | -0.7 |
| May 2, 2026 | 42.7 | 55.9 | 25.0 | 45.6 | 8.4 | 80.5 | +0.3 |
| May 1, 2026 | 42.4 | 55.9 | 25.0 | 44.5 | 8.4 | 80.5 | 0.0 |
| Apr 26, 2026 | 42.4 | 55.9 | 25.0 | 44.4 | 8.4 | 80.5 | +0.6 |
| Apr 23, 2026 | 41.8 | 55.9 | 25.0 | 44.4 | 8.4 | 76.4 | 0.0 |
TEVA — Pillar Breakdown
Quality
— 58.7/100 (25%)Teva Pharmaceutical Industries Limited shows solid profitability with healthy returns on capital and reasonable margins.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 44.5/100 (20%)Teva Pharmaceutical Industries Limited shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 8.5/100 (15%)Teva Pharmaceutical Industries Limited presents elevated risk with concerns around leverage or financial stability.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 70.5/100 (15%)Teva Pharmaceutical Industries Limited trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 25/100 (25%)Teva Pharmaceutical Industries Limited operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TEVA.
Score Composition
Financial Data
More Stock Analysis
How is the TEVA UQS Score Calculated?
The UQS (Unified Quality Score) for Teva Pharmaceutical Industries Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Teva Pharmaceutical Industries Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Teva Pharmaceutical Industries Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.